Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) and Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.
Profitability
This table compares Ensysce Biosciences and Axsome Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ensysce Biosciences | -280.53% | -2,550.30% | -320.49% |
| Axsome Therapeutics | -24.68% | -265.55% | -28.10% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Ensysce Biosciences and Axsome Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ensysce Biosciences | 1 | 0 | 1 | 0 | 2.00 |
| Axsome Therapeutics | 1 | 2 | 17 | 1 | 2.86 |
Ensysce Biosciences currently has a consensus price target of $2.00, suggesting a potential upside of 344.44%. Axsome Therapeutics has a consensus price target of $274.68, suggesting a potential upside of 90.67%. Given Ensysce Biosciences’ higher possible upside, analysts plainly believe Ensysce Biosciences is more favorable than Axsome Therapeutics.
Institutional & Insider Ownership
5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Ensysce Biosciences and Axsome Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ensysce Biosciences | $5.07 million | 1.73 | -$10.18 million | ($2.76) | -0.16 |
| Axsome Therapeutics | $638.50 million | 11.82 | -$183.17 million | ($3.75) | -38.42 |
Ensysce Biosciences has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Ensysce Biosciences has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Summary
Axsome Therapeutics beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks.
About Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
